Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000180512 | SCV000232969 | uncertain significance | not provided | 2015-08-24 | criteria provided, single submitter | clinical testing | |
Center for Pediatric Genomic Medicine, |
RCV000180512 | SCV000281033 | uncertain significance | not provided | 2015-07-14 | criteria provided, single submitter | clinical testing | Converted during submission to Uncertain significance. |
Labcorp Genetics |
RCV000640830 | SCV000762431 | benign | Alpha thalassemia-X-linked intellectual disability syndrome | 2023-12-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002517765 | SCV003549558 | uncertain significance | Inborn genetic diseases | 2021-02-24 | criteria provided, single submitter | clinical testing | The c.3091G>A (p.G1031S) alteration is located in exon 9 (coding exon 9) of the ATRX gene. This alteration results from a G to A substitution at nucleotide position 3091, causing the glycine (G) at amino acid position 1031 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000640830 | SCV001462654 | uncertain significance | Alpha thalassemia-X-linked intellectual disability syndrome | 2020-09-16 | no assertion criteria provided | clinical testing |